Replies to post #1096 on Alaunos Therapeutics Inc (TCRT)

[WalkingHome]

"2. Results may be observable on a per patient basis quickly - weeks."

A Phase II Study Using Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer - http://ClinicalTrials.gov. Starts in 5 days
A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping...
A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in...
clinicaltrials.gov
9:44 AM · Sep 25, 2019·Twitter for iPhone
6
Retweets
20
Likes
ThomasUBarton
@ThomasUBarton1
·
7h
Replying to
@ThomasUBarton1
2. Results may be observable on a per patient basis quickly - weeks.
https://twitter.com/ThomasUBarton1/status/1176854964448006150

[jondoeuk]

''Be Negative Nancy if you want....

Rosenberg said he is speeding up enrollment to 1 patient per cohort / every 3 weeks in the other Viral TCR NeoAntigen Trial per video April 2019.''

A few days around the estimated start date was the 9th and now it has been changed to the 11th. But this has been the case for the last few months (since Sept).

''While you wait to the year 2028

Dr Drew Deniger + Ziopharm is staffing up with Ana Beatriz Korngold, Tom Spencer, + others in Houston... to launch ZIOP's own controlled TCR NeoAntigen Trial... do you think it will be Phase 1?... or Phase 2/3? and will it be as slow as Govt Longitudinal study?... if they start showing efficacy... game set match - Jon Doe Uk, innit?''

Knowing this company I wouldn't expect much. If the trial does happen, I will likely be a PhI and should move slightly faster (once open and enrolling) than the one at the NCI. Also, being an open label (I assume) they can report data when they see fit.